Search results for "CUSHING DISEASE"

showing 5 items of 5 documents

INSULIN SECRETION AND SENSITIVITY DURING PASIREOTIDE TREATMENT IN PATIENTS WITH RECURRENT CUSHING DISEASE: A CASE SERIES

2015

CUSHING DISEASE
researchProduct

EFFECTS OF PASIREOTIDE TREATMENT ON CARDIOMETABOLIC RISK IN PATIENTS WITH CUSHING’S DISEASE : AN ITALIAN, MULTICENTER STUDY

2017

CUSHING DISEASESettore MED/13 - Endocrinologia
researchProduct

Pasireotide versus pituitary surgery: a retrospective analysis of 12 months of treatment in patients with Cushing’s disease

2017

Pituitary surgery represents the first-line treatment for most patients with Cushing’s disease (CD). In the case of surgery failure, additional treatment options are required. Pasireotide has shown favourable results in the first-line treatment of patients with CD, who are not candidates for surgery or in the second-line when surgery has failed. The aim of the current study is to compare the effects of surgery and pasireotide treatment in a cohort of patients with CD, and to evaluate the differences in response rate in terms of hormonal and clinical control, and improvement of metabolic complications

Pituitary glandmedicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismpasireotide cushing diseaseSettore MED/13 - Endocrinologia03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyDiabetes mellitusmedicineIn patientbusiness.industryPituitary ACTH hypersecretionRetrospective cohort studyCushing's diseasemedicine.diseasePasireotideSurgerymedicine.anatomical_structurechemistry030220 oncology & carcinogenesisPituitary surgerybusinessEndocrine
researchProduct

Circulating adipokine levels in diabetic patients with Cushing disease on pasireotide treatment compared with patients with type 2 diabetes mellitus

2017

cushing diseaseSettore MED/13 - Endocrinologia
researchProduct

Comparison of clinical and metabolic effects of pasireotide and pituitary surgery in Cushing disease

2017

Pituitary surgery represents the first-line treatment for most patients with Cushing’s disease (CD). In the case of surgery failure, additional treatment options are required. Pasireotide has shown favourable results in the first-line treatment of patients with CD, who are not candidates for surgery or in the second-line when surgery has failed. The aim of the current study is to compare the effects of surgery and pasireotide treatment in a cohort of patients with CD, and to evaluate the differences in response rate in terms of hormonal and clinical control, and improvement of metabolic complications.

pasireotide cushing diseaseSettore MED/13 - Endocrinologia
researchProduct